Neurodegenerative conditions rarely announce themselves dramatically. Parkinson's disease, for example, may progress for years before symptoms become clinically apparent. In a classic post-mortem study, Fearnley and Lees (1991) estimated a presymptomatic phase of about five years from the onset of neuronal loss, and calculated that by the time symptoms appeared, about 68% of pigmented neurons had been lost in the most affected region of the substantia nigra (and about 48% across the caudal nigra as a whole). The Movement Disorder Society has since published research criteria for this prodromal stage (Berg et al., 2015). By the time patients seek care, significant neurological changes have already occurred. This reality makes early detection not just valuable — but essential for preserving function and quality of life.
Continuous monitoring technology captures the variability that episodic clinic visits miss. A patient's movement patterns fluctuate throughout the day, across medication cycles, and in response to fatigue or stress — one reason a Movement Disorder Society task force has pointed to technology-based monitoring as an opportunity in Parkinson's care (Espay et al., 2016). Single assessments cannot capture this complexity, but longitudinal data reveals patterns that inform better treatment decisions and enable proactive rather than reactive care.
Remote assessment also brings clinical insight into patients' real-world environments. How someone moves in a clinic corridor differs from navigating their own home: in one study, people with Parkinson's disease and healthy older adults alike walked more slowly and more variably in daily life than in the lab (Del Din et al., 2016). Technology bridges this gap, providing functional data from where patients actually live — the movements that matter most for maintaining independence.
For healthcare organizations, adopting continuous monitoring capabilities represents a competitive advantage. Practices that offer sophisticated movement tracking demonstrate commitment to innovation while building stronger patient relationships through more personalized, data-informed care that catches problems before they become crises.
References
- Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283-2301. doi:10.1093/brain/114.5.2283
- Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Movement Disorders. 2015;30(12):1600-1611. doi:10.1002/mds.26431
- Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: challenges and opportunities. Movement Disorders. 2016;31(9):1272-1282. doi:10.1002/mds.26642
- Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. Journal of NeuroEngineering and Rehabilitation. 2016;13:46. doi:10.1186/s12984-016-0154-5